



ABIVAX to Participate in “Corporate Access” Event in San Francisco, January 8 – 10, 2018

December 21, 2017

PARIS, Dec. 21, 2017, 8:00 am. CET – ABIVAX (Euronext Paris: FR0012333284 – ABVX), a biotechnology company harnessing the immune system to develop a functional cure for HIV and treatments for inflammatory/autoimmune diseases and cancer, today announces that its senior management team will host institutional investor and partnering meetings at the LifeSci Advisors Corporate Access Event taking place in San Francisco, January 8-10, 2018.

To schedule a meeting with ABIVAX, investors can register on the online system managed by the Company's US investor relations firm, LifeSci Advisors, LLC, or make a request via e-mail at [This email address is being protected from spambots. You need JavaScript enabled to view it.](mailto:This_email_address_is_being_protected_from_spambots.You_need_JavaScript_enabled_to_view_it.>Access@LifeSciAdvisors.com)>Access@LifeSciAdvisors.com.